Literature DB >> 1785725

Dose response to butorphanol administered subcutaneously to increase visceral nociceptive threshold in dogs.

D C Sawyer1, R H Rech, R A Durham, T Adams, M A Richter, E L Striler.   

Abstract

Butorphanol (0.025, 0.05, 0.1, 0.2, 0.4, and 0.8 mg/kg of body weight, and placebo) was given SC to 8 healthy unmedicated dogs to determine its efficacy for visceral analgesia, using a colonic balloon for minimal threshold nociceptor stimulation. Degree of sedation; systolic, diastolic, and mean arterial pressure; and pulse rate were recorded. The highest 3 dosages, 0.2, 0.4, and 0.8 mg/kg, were found to be most effective, with 0.8 mg/kg the only dosage that was significantly different from control responses at the 45-minute interval. Duration of analgesia ranged from 23 to 53 minutes for all 6 dosages and dosing durations were not significantly different from one another. Blood pressures did not change, but pulse rate was significantly decreased by 0.8 mg of butorphanol/kg. We concluded that butorphanol is an effective visceral analgesic of relatively short duration in the dog.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1785725

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  4 in total

1.  Experimental colitis alters visceromotor response to colorectal distension in awake rats.

Authors:  O Morteau; T Hachet; M Caussette; L Bueno
Journal:  Dig Dis Sci       Date:  1994-06       Impact factor: 3.199

2.  A comparison of the analgesic effects of butorphanol with those of meloxicam after elective ovariohysterectomy in dogs.

Authors:  Nigel Caulkett; Matt Read; David Fowler; Cheryl Waldner
Journal:  Can Vet J       Date:  2003-07       Impact factor: 1.008

3.  Effects of combined opioids on pain and mood in mammals.

Authors:  Richard H Rech; David J Mokler; Shannon L Briggs
Journal:  Pain Res Treat       Date:  2012-03-21

4.  Management of veterinary anaesthesia in small animals: A survey of current practice in Quebec.

Authors:  Geoffrey Truchetti; Colombe Otis; Anne-Claire Brisville; Guy Beauchamp; Daniel Pang; Eric Troncy
Journal:  PLoS One       Date:  2020-01-16       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.